FrancophonIA/ELRC3.0 huggingface dataset:
English: Mechanism: CYP3A4/Pgp inhibition by conivaptan and paritaprevir/ ritonavir/ombi tasvir
Croatian: CYP3A4/Pgp inhibicija konivaptano m i paritaprevir om/ritonavi rom/ombita svirom
English: If tacrolimus or sirolimus are used together with Viekirax and dasabuvir, caution is advised, and recommended doses and monitoring strategies can be found in section 4.5.
Croatian: Potreban je oprez ako se takrolimus ili sirolimus primjenjuju zajedno s lijekom Viekirax i dasabuvirom, a preporučene doze i strategije za praćenje nalaze se u dijelu 4.5. Everolimus se ne može primjenjivati jer ne postoje odgovarajuće jačine lijeka za prilagodbu doziranja.
English: HCV RNA from nadir, or HCV RNA persistently ≥ 25 IU/mL with at least 6 weeks of treatment.
Croatian: HCV RNK od ≥ 25 IU/ml uz najmanje 6 tjedana liječenja.
English: PEARL-IV - genotype 1a, treatment-naïve, without cirrhosis
Croatian: PEARL-IV - prethodno neliječeni ispitanici s infekcijom genotipom 1a, bez ciroze
English: Mechanism: CYP3A4/OA TP1B inhibition
Croatian: CYP3A4/ OATP1B inhibicija
English: Increase in paritaprevir exposures may be due to inhibition of OATP1B1/B3 and CYP3A by atazanavir.
Croatian: : Povećanje izloženosti paritaprevir u moglo bi biti posljedica inhibicije OATP1B1/ B3 i
English: ↑ norgestrel ↑ nor elgestromine ombitasvir paritaprevir
Croatian: ↑ norgestrel norelgestromin ombitasvir paritaprevir
English: TURQUOISE-I: treatment-naïve or pegIFN + RBV-experienced with HCV GT1 or GT4/HIV-1 coinfection, without cirrhosis or with compensated cirrhosis
Croatian: TURQUOISE-I: ispitanici bez ciroze ili s kompenziranom cirozom, prethodno neliječeni ili prethodno liječeni pegIFN i RBV, s istodobnom infekcijom HCV-om genotipa 1 ili 4 i HIV-om tipa 1 Dizajn:
English: SAPPHIRE-II - genotype 1, pegIFN+RBV-experienced, without cirrhosis
Croatian: SAPPHIRE-II - ispitanici prethodno liječeni pegIFN i RBV s infekcijom genotipom 1, bez ciroze Dizajn:
English: Mechanism: BCRP inhibition by paritaprevir, ritonavir and dasabuvir.
Croatian: Mehanizam : BCRP inhibicija paritaprevir om, ritonavirom i dasabuviro m.
English: Ritonavir plasma concentrations increased when renal function was reduced: Cmax and AUC values were 26% to 42% higher, 48% to 80% higher and 66% to 114% higher in subjects with mild, moderate and severe renal impairment, respectively.
Croatian: Koncentracija ritonavira u plazmi se povećala pri smanjenoj funkciji bubrega: vrijednosti Cmax i AUC bile su od 26% do 42% veće u ispitanika s blagim oštećenjem, od
English: This regimen can be used in the absence of extensive PI resistance (i.e. lack of darunavir associated RAMs), see also section
Croatian: Ovaj režim liječenja može se koristiti ako nema izražene rezistencije na inhibitore proteaze (tj. ako nema mutacija povezanih s rezistencijom na darunavir),
English: For patients coadministered ribavirin refer to the Summary of Product Characteristics of ribavirin.
Croatian: Za bolesnice koje istodobno primaju ribavirin, pročitajte i sažetak opisa svojstava lijeka za ribavirin.
English: SVR12 for genotype 1-infected peginterferon+ribavirin-experienced subjects in SAPPHIRE-II
Croatian: Tablica 11. SVR12 za ispitanike prethodno liječene peginterferonom i ribavirinom s infekcijom genotipom 1 u ispitivanju SAPPHIRE-II
English: Alprazolam Viekirax + dasabuvir alprazolam
Croatian: Viekirax + dasabuvir alprazolam
English: It is not known whether the active substances in Viekirax (ombitasvir, paritaprevir and ritonavir) pass into breast milk.
Croatian: Viekirax (ombitasvir, paritaprevir i ritonavir) u majčino mlijeko.
English: Co-administration of Viekirax with everolimus is not recommended because of a significant increase in everolimus exposures which cannot be properly dose adjusted with available dose strengths (see section 4.4).
Croatian: Istodobna primjena lijeka Viekirax s everolimusom se ne preporučuje zbog značajnog porasta izloženosti everolimusu,
English: The treatment-experienced subjects studied were primarily pegIFN/RBV null responders.
Croatian: Prethodno liječeni ispitanici uglavnom nisu imali odgovor na liječenje peginterferonom i ribavirinom (pegIFN/RBV).
English: • ticagrelor
Croatian: • tikagrelor
English: Paritaprevir, ritonavir and dasabuvir are inhibitors of BCRP in vivo.
Croatian: Lijekovi koji se prenose putem BCRP prijenosnika Paritaprevir, ritonavir i dasabuvir su inhibitori prijenosnika BCRP in vivo.
English: Viekirax and dasabuvir without ribavirin or with weight-based ribavirin for 12 weeks
Croatian: Viekirax i dasabuvir tijekom 12 tjedana bez ribavirina ili s ribavirinom čija je doza temeljena na težini
English: Patient population
Croatian: Skupina bolesnika
English: − Feel sick (nauseous), are sick (vomit) or lose your appetite
Croatian: − mučnina, povraćanje ili gubitak teka
English: Viekirax in combination with ribavirin is recommended in genotype 4 infection.
Croatian: Kod bolesnika s infekcijom genotipom 4 preporučuje se kombinirano liječenje lijekom Viekirax i ribavirinom.
English: ↑ trimethoprim ombitasvir
Croatian: ↑ trimetoprim ombitasvir
English: Concomitant use is contraindicated (see section
Croatian: Istodobna primjena je kontraindicirana (vidjeti
English: Mechanism: possibly due to UGT1A1 inhibition by paritaprevir, ombitasvir and dasabuvir.
Croatian: Mehanizam : mogao bi biti posljedica inhibicije UGT1A1 koju uzrokuju paritaprevir, ombitasvir i dasabuvir.
English: ↓ es citalopram
Croatian: Sdezmetilcitalopram
English: A temporary suspension of fluvastatin and pitavastatin is recommended for the duration of treatment with Viekirax.
Croatian: Tijekom liječenja lijekom Viekirax preporuča se privremeni prestanak terapije fluvastatinom i pitavastatinom.
English: Viekirax with weight-based ribavirin for 12 or 16 weeks
Croatian: Viekirax tijekom 12 ili 16 tjedana s ribavirinom čija je doza temeljena na težini
English: Treated subjects (N = 63) had a median age of 51 years (range: 31 to 69); 24% were Black; 19% had compensated cirrhosis; 67% were treatment-naïve; 33% had failed prior treatment with pegIFN/RBV; 89% had HCV genotype 1a infection.
Croatian: 24% bili su crnci; 19% imalo je kompenziranu cirozu; 67% nije bilo prethodno liječeno; 33% bilo je prethodno neuspješno liječeno pegIFN/RBV-om; 89% imalo je infekciju HCV-om genotipa 1a.
English: Mechanism: CYP3A4 inhibition by protease inhibitors.
Croatian: CYP3A4 inhibicija inhibitorima proteaza.
English: Viekirax + dasabuvir ciclosporin
Croatian: Viekirax + dasabuvir ciklosporin
English: − Notice yellowing of your skin or eyes
Croatian: − žuta boja kože ili očiju − tamnija boja mokraće nego inače
English: Following a 600 mg dose of 14C -ritonavir oral solution, 86.4% of the radioactivity was recovered in the faeces and 11.3% of the dose was excreted in the urine.
Croatian: 86,4% radioaktivnosti pronađeno je u fecesu, a 11,3% doze izlučeno je kroz mokraću.
English: Mechanism: CYP3A4/Pgp inhibition by clarithromyci n and ritonavir.
Croatian: CYP3A4/Pgp inhibicija klaritromici nom i ritonavirom.
English: Adverse drug reactions identified with Viekirax in combination with dasabuvir with and without ribavirin
Croatian: Tablica 3. Nuspojave na lijek utvrđene kod primjene lijeka Viekirax u kombinaciji s dasabuvirom, s ribavirinom ili bez njega
English: Smephenytoin
Croatian: Smefenitoin
English: HCV Genotype 1b Viekirax and dasabuvir
Croatian: HCV genotipa 1b Viekirax i dasabuvir
English: HIV ANTIVIRALS: INTEGRASE STRAND TRANSFER INHIBITOR Dolutegravir
Croatian: ANTIVIROTICI ZA LIJEČENJE HIV-a: INHIBITORI PRIJENOSA LANCA INTEGRAZE
English: SVR12 for genotype 1b-infected peginterferon+ribavirin-experienced subjects in PEARL II
Croatian: Tablica 12. SVR12 za ispitanike prethodno liječene peginterferonom i ribavirinom s infekcijom genotipom 1b u ispitivanju PEARL II
English: Ritonavir is predominantly metabolised by CYP3A and to a lesser extent, by CYP2D6.
Croatian: Ritonavir se najvećim dijelom metabolizira posredstvom CYP3A, a u manjoj mjeri posredstvom
English: D168Y V36Ac, V36Mc, F43Lc, D168H, E357Kc NS5A M28T M28Ve Q30Re Y93H H58D, H58P, Y93N NS5B A553T S556G C316Y, M414T, G554S, S556R, G558R, D559G, D559N, Y561H a. Observed in at least 2 subjects of the same subtype.
Croatian: C316Y, M414T, G554S, S556R, G558R, D559G, D559N, Y561H a.
English: ↔ ombitasvir/paritaprevir (based on the cross-study comparison)
Croatian: ↔ ombitasvir/paritaprevir/ (na temelju usporedbe podataka iz različitih ispitivanja)
English: The efficacy of Viekirax has not been established in patients with HCV genotypes 2, 3, 5 and 6; therefore Viekirax should not be used to treat patients infected with these genotypes.
Croatian: Za preporučeno doziranje kod različitih genotipova HCV-a vidjeti dio 4.2. Za virološku i kliničku aktivnost protiv pojedinih genotipova vidjeti dio 5.1. Djelotvornost lijeka Viekirax nije ustanovljena u bolesnika s HCV-om genotipova 2, 3, 5 i 6 te se stoga Viekirax ne smije koristiti u liječenju bolesnika s infekcijom ovim genotipovima.
English: CYP3A4 inhibition by ritonavir
Croatian: CYP3A4 inhibicija ritonavirom
English: Viekirax and dasabuvir with weight-based ribavirin for 12 or 24 weeks
Croatian: Viekirax i dasabuvir tijekom 12 ili 24 tjedna s ribavirinom čija je doza temeljena na težini
English: Mechanism: CYP2C19 induction by ritonavir
Croatian: Mehanizam: indukcija CYP2C19 ritonavirom
English: NA No dose adjustment required for cyclobenzaprine; increase dose if clinically indicated.
Croatian: NP Nije potrebno prilagođavati dozu za ciklobenzaprin; primijeniti veću dozu ako je to klinički indicirano.
English: The EC50 of paritaprevir against genotype 1a-H77 and 1b-Con1 strains in the HCV replicon cell culture assay was 1.0 and 0.21 nM, respectively.
Croatian: U testu replikona HCV-a u staničnoj kulturi, EC50 paritaprevira protiv sojeva genotipa 1a-H77 iznosio je 1,0 nM, a protiv sojeva genotipa 1b-Con1 0,21 nM.
English: Prior pegIFN/RBV null responder Prior pegIFN/RBV partial responder Prior pegIFN/RBV relapser Outcome for subjects without SVR12 On-treatment VF
Croatian: Djelomičan odgovor na prethodno liječenje kombinacijom pegIFN/RBV Relaps nakon prethodnog liječenja kombinacijom pegIFN/RBV Ishodi za ispitanike bez SVR12 Virološki neuspjeh tijekom liječenja
English: Package leaflet: Information for the patient Viekirax 12.5 mg/75 mg/50 mg film-coated tablets ombitasvir/paritaprevir/ritonavir This medicine is subject to additional monitoring.
Croatian: Uputa o lijeku: Informacije za bolesnika Viekirax 12,5 mg/75 mg/50 mg filmom obložene tablete ombitasvir/paritaprevir/ritonavir
English: Viekirax with ribavirin & without dasabuvir was evaluated for 12 weeks in genotype 1 treatment naive and treatment experienced non-cirrhotic subjects in a phase 2 study M11-652 (AVIATOR).
Croatian: Liječenje lijekom Viekirax s ribavirinom i bez dasabuvira ispitivalo se tijekom 12 tjedana u prethodno liječenih te prethodno neliječenih ispitanika s infekcijom genotipom 1 bez ciroze u ispitivanju faze II
English: 250 mg single dose
Croatian: karisoprodol 250 mg pojedinačna doza
English: Pitavastatin Mechanism: OATP1B inhibition by paritaprevir
Croatian: Mehanizam : OATP1B inhibicija paritaprevir om
English: Baseline platelet count, median (× 109/L)
Croatian: Početne razine albumina, medijan g/L
English: Buprenorphine / naloxone
Croatian: buprenorfin / nalokson
English: The EC50 of ombitasvir against genotype 1a-H77 and 1b-Con1 strains in HCV replicon cell culture assays was 14.1 and 5 pM, respectively.
Croatian: U testovima replikona HCV-a u staničnoj kulturi, EC50 ombitasvira protiv sojeva genotipa 1a-H77 iznosio je 14,1 pM, a protiv sojeva genotipa 1b-Con1 5 pM.
English: CALCIUM CHANNEL BLOCKERS Amlodipine
Croatian: BLOKATORI KALCIJEVIH KANALA amlodipin pojedinačna doza od 5 mg
English: PEARL-II - genotype 1b, pegIFN+RBV-experienced, without cirrhosis
Croatian: PEARL-II - ispitanici prethodno liječeni pegIFN i RBV s infekcijom genotipom 1b, bez ciroze Dizajn:
English: Co-administration with other direct-acting antivirals against HCV
Croatian: ANTIVIROTICI ZA LIJEČENJE HCV-a
English: Mechanism: CYP2C19 induction by ritonavir.
Croatian: Mehanizam : CYP2C19 indukcija ritonavirom.
English: Mechanism: CYP3A4 inhibition by
Croatian: Mehanizam : CYP3A4 inhibicija kobicistato m
English: ↑ ticagrelor
Croatian: ↑ tikagrelor
English: CYP3A4 inhibition by ritonavir.
Croatian: CYP3A4 inhibicija ritonavirom.
English: TURQUOISE-III: treatment-naïve or pegIFN + RBV-experienced with compensated cirrhosis Design:
Croatian: TURQUOISE-III: ispitanici s kompenziranom cirozom, prethodno neliječeni ili prethodno liječeni pegIFN i RBV Dizajn:
English: In genotype 4a, resistance to paritaprevir or ombitasvir by variants in NS3 or NS5A, respectively, selected in cell culture were phenotypically characterised.
Croatian: NS3 te rezistencija na ombitasvir uzrokovana varijantama u NS5A, koje su izdvojene u staničnim kulturama.
English: A reduction in colchicine dosage or an interruption of colchicine treatment is recommended in patients with normal renal or hepatic function if treatment with Viekirax with or without dasabuvir is required (see section 4.5).
Croatian: Ako je potrebno liječenje lijekom Viekirax s dasabuvirom ili bez njega, kod bolesnika koji imaju urednu funkciju bubrega ili jetre preporučuje se smanjenje doze kolhicina ili prekid liječenja s kolhicinom (vidjeti dio 4.5).
English: NA No dose adjustment necessary for paracetamol when administered with Viekirax with or without dasabuvir.
Croatian: NP Nije potrebno prilagođavati dozu za paracetamol kada se primjenjuje s lijekom Viekirax s dasabuvirom ili bez njega.
English: SVR12 for HCV Genotype 4-Infected Subjects with Compensated Cirrhosis Ombitasvir + Paritaprevir + Ritonavir with RBV 12 Weeks
Croatian: Ombitasvir + paritaprevir + ritonavir s RBV 12 tjedana
English: Ethinyloestradiolcontaining oral contraceptives are contraindicated (see section 4.3).
Croatian: Oralni kontraceptivi koji sadrže etinilestradiol su kontraindicirani (vidjeti dio
English: NA No dose adjustment needed for abacavir or lamivudine when coadministered with Viekirax with or without dasabuvir.
Croatian: NP Nije potrebno prilagođavati dozu abakavira ili lamivudina kada se primjenjuju s lijekom Viekirax s dasabuvirom ili bez njega.
English: Upon completion of Viekirax and dasabuvir treatment, the appropriate dose and dosing frequency of tacrolimus should be guided by assessment of tacrolimus blood concentrations.
Croatian: odgovarajuću dozu i učestalost primjene takrolimusa treba odrediti na temelju koncentracija takrolimusa u krvi.
English: Clinical monitoring and dose adjustment may be needed for other CYP1A2 substrates (e.g. ciprofloxacin, cyclobenzaprine, theophylline and caffeine).
Croatian: Klinički nadzor i prilagodba doze mogu biti potrebni za ostale supstrate za CYP1A2 (npr.
English: Treatment duration 12 weeks
Croatian: Skupina liječena 12
English: Hepatic decompensation and hepatic failure, including liver transplantation or fatal outcomes, have been reported postmarketing in patients treated with Viekirax with and without dasabuvir and with and without ribavirin.
Croatian: Nakon stavljanja lijeka u promet, u bolesnika liječenih lijekom Viekirax u kombinaciji s dasabuvirom ili bez njega te u kombinaciji s ribavirinom ili bez njega prijavljeni su dekompenzacija jetre i zatajenje jetre, uključujući slučajeve koji su završili transplantacijom jetre ili smrtnim ishodom.
English: Viekirax and dasabuvir with RBV 12-week arm
Croatian: Viekirax i dasabuvir s RBV-om
English: If statin treatment is required during the treatment period, a switch to dose reduced pravastatin or rosuvastatin is possible.
Croatian: moguće je prebacivanje na smanjene doze pravastatina ili rosuvastatina.
English: ↓ esomeprazole, lansoprazole
Croatian: Kliničke napomene esomeprazo l lanzoprazol
English: Dabigatran etexilate Mechanism: Intestinal Pgp inhibition by paritaprevir and ritonavir.
Croatian: Mehanizam : inhibicija crijevnog Pgp paritaprevir om i ritonavirom.
English: Mechanism: OATP1B inhibition by paritaprevir and BCRP inhibition by paritaprevir, ritonavir or dasabuvir.
Croatian: Mehanizam paritaprevir inhibira OATP1B, a paritaprevir, ritonavir ili dasabuvir inhibiraju BCRP.
English: Skin and subcutaneous tissue disorders Very common
Croatian: Poremećaji kože i potkožnog tkiva vrlo često pruritus često pruritus rijetko angioedem angioedem
English: Viekirax with or without dasabuvir ethinyloestra diol
Croatian: Viekirax s dasabuvirom ili bez njega etinilestradiol
English: Mechanism: CYP3A4 induction by phenytoin.
Croatian: Mehanizam : Indukcija CYP3A4 fenitoinom
English: Expected: ↑ sildenafil
Croatian: Očekuje se: ↑ enkorafenib
English: No dose adjustment is necessary for norethindrone or Viekirax with or without dasabuvir.
Croatian: Nije potrebna prilagodba doze noretindrona niti lijeka Viekirax s dasabuvirom ili bez njega.
English: Viekirax and dasabuvir with weight-based ribavirin for 12 weeks
Croatian: Viekirax i dasabuvir tijekom 12 tjedana s ribavirinom čija je doza temeljena na težini
English: 25 mg once daily administered in the
Croatian: 25 mg jedanput na dan, ujutro s hranom
English: Viekirax with or without dasabuvir coadminstered with or without weight-based ribavirin for 12 or 24 weeks
Croatian: Viekirax s dasabuvirom ili bez njega tijekom 12 ili 24 tjedna, u kombinaciji s ribavirinom čija je doza temeljena na težini ili bez njega
English: paritaprevir ombitasvir
Croatian: paritaprevir ombitasvir dabigatranet eksilat
English: Arm B: Viekirax and dasabuvir + RBV (24 weeks)
Croatian: skupina A: Viekirax i dasabuvir + RBV (12 tjedana) skupina B: Viekirax i dasabuvir + RBV (24 tjedna)
English: Overall SVR12 Outcome for subjects without SVR12 On-treatment VF Relapse Other * Ombitasvir tablets, paritaprevir tablets and ritonavir capsules administered separately.
Croatian: Ostalo * Tablete ombitasvira, tablete paritaprevira i kapsule ritonavira primjenjivale su se odvojeno.
English: Mechanism: possibly due to UGT inhibition by paritaprevir, ombitasvir and dasabuvir.
Croatian: Mehanizam : mogao bi biti posljedica inhibicije UGT-a koju uzrokuju paritaprevir, ombitasvir i dasabuvir.
English: Concomitant use with fluvastatin and pitavastatin is not recommended (see section 4.4).
Croatian: Ne preporuča se istodobna primjena s fluvastatinom i pitavastatinom. (vidjeti dio
English: Viekirax without dasabuvir omeprazole
Croatian: Viekirax bez dasabuvira vorikonazol
English: No dose adjustment needed for Viekirax with or without dasabuvir.
Croatian: Nije potrebno prilagođavati dozu lijeka Viekirax s ili bez dasabuvira.
English: ↑ fexofenadine
Croatian: ↑ feksofenadin
English: NA No dose adjustment needed for sofosbuvir when administered with Viekirax with or without dasabuvir.
Croatian: NP Nije potrebno prilagođavati dozu sofosbuvira kada se primjenjuje s lijekom Viekirax s dasabuvirom ili bez njega.
English: Clinical trials in treatment-naïve adults
Croatian: Klinička ispitivanja u ispitanika s kompenziranom cirozom
English: Following administration of Viekirax
Croatian: Nakon primjene lijeka Viekirax
English: Note: Doses used for Viekirax and dasabuvir were: ombitasvir 25 mg, paritaprevir 150 mg, ritonavir 100 mg, once daily and dasabuvir 400 mg twice daily or 250 mg twice daily.
Croatian: 150 mg, ritonavir 100 mg jedanput na dan i dasabuvir 400 mg dvaput na dan ili 250 mg dvaput na dan.
English: Mechanism: UGT1A1 inhibition by paritaprevir, ombitasvir and dasabuvir.
Croatian: UGT1A1 inhibicija paritaprevir om, ombitasviro m i dasabuviro m.
English: Table 2 provides the Least Squares Means Ratio (90% Confidence Interval) effect on concentration of Viekirax with or without dasabuvir and concomitant medicinal products.
Croatian: (90% interval pouzdanosti) na koncentraciju lijeka Viekirax, s dasabuvirom ili bez njega, te istodobno primijenjenih lijekova.
English: Viekirax and dasabuvir for 12 weeks With RBV
Croatian: Viekirax i dasabuvir tijekom 12 tjedana bez ribavirina
English: CYP3A4 induction by phenobarbital.
Croatian: Mehanizam : Indukcija CYP3A4 fenobarbital om.
English: No dose adjustment is necessary for emtricitabine/tenofovir and Viekirax with or without dasabuvir.
Croatian: Nije potrebno prilagođavati dozu za emtricitabin/tenofovir niti
English: If rosuvastatin treatment is required during the treatment period, the maximum daily dose of rosuvastatin should be 5 mg (see section 4.5, Table 2).The increase in rosuvastatin when combined with Viekirax without dasabuvir is less pronounced.
Croatian: Ako je istodobno liječenje rosuvastatinom neophodno, maksimalna dnevna doza rosuvastatina smije biti 5 mg (vidjeti dio 4.5, Tablica 2).
English: Viekirax without dasabuvir
Croatian: Viekirax bez dasabuvira
English: Subjects (N=135) had a median age of 51 years (range: 19 to 70); 63,7% were treatment-naïve, 17.0% were prior pegIFN/RBV null responders, 6.7% were prior pegIFN/RBV partial responders, 12.6% were prior pegIFN/RBV relapsers; 65.2%were male; 8.9% were Black, 69.6% had baseline HCV RNA levels at least 800,000 IU/mL; 6.7% had bridging fibrosis (F3).
Croatian: Medijan dobi ispitanika (N=135) iznosio je 51 godinu (raspon: 19 do 70); 63,7% bili su prethodno neliječeni, 17,0% nisu odgovarali na prethodno liječenje pegIFN/RBV, 6,7% su djelomično odgovarali na prethodno liječenje pegIFN/RBV, 12,6% je imalo relaps nakon prethodnog liječenja pegIFN/RBV;
English: NA Concomitant use of Viekirax with dasabuvir is contraindicated (see section 4.3).
Croatian: NP Istodobna primjena lijeka Viekirax s dasabuvirom je kontraindicirana (vidjeti dio
English: 400 mg twice daily
Croatian: raltegravir 400 mg dvaput na dan
English: Everolimus cannot be used due to lack of suitable dose strengths for dose adjustments.
Croatian: čija se doza ne može pravilno prilagoditi s dostupnim jačinama lijeka
English: Mechanism: CYP3A4 inhibition by ritonavir
Croatian: Mehanizam: CYP3A4 inhibicija ritonavirom
English: Expected: lomitapide
Croatian: Očekuje se: ↑ lomitapid
English: Patients who are taking ethinyloestradiol-containing medicinal products (i.e. most combined oral contraceptives or contraceptive vaginal rings) must switch to an alternative method of contraception (e.g., progestin only contraception or non-hormonal methods) prior to initiating Viekirax with or without dasabuvir therapy (see sections 4.3 and 4.5).
Croatian: kontracepcija samo progestinom ili nehormonske metode) prije započinjanja liječenja lijekom Viekirax s dasabuvirom ili bez njega (vidjeti dijelove 4.3 i 4.5).
English: Disopyramide
Croatian: dezmetilcitalopram
English: Co-administration of Viekirax with or without dasabuvir with medicinal products that are primarily metabolized by UGT1A1 result in increased plasma concentrations of such medicinal products; routine clinical monitoring is recommended for narrow therapeutic index medicinal products (i.e. levothyroxine).
Croatian: povećava koncentracije tih lijekova u plazmi; preporuča se rutinsko kliničko praćenje za lijekove s uskim terapijskim indeksom (tj. levotiroksin).
English: Target
Croatian: Ciljno mjesto
English: CONTRACEPTIVES
Croatian: Lijek/
English: ↑ salmeterol
Croatian: Očekuje se: ↑ salmeterol
English: The SVR12 rates in HCV/HIV-1 co-infected subjects were thus consistent with SVR12 rates in the phase 3 trials of HCV mono-infected subjects.
Croatian: om tipa 1 odgovarala je stopi SVR12 u ispitivanjima faze III u ispitanika s infekcijom samo HCV-om.
English: Expected: ↓ombitasvir ↓ paritaprevir ↓ dasabuvir
Croatian: Očekuje se: ↓ombitasvir ↓ paritaprevir ↓ dasabuvir
English: Medicinal products transported by BCRP
Croatian: Lijekovi koji se prenose putem P-gp-a u crijevima
English: A
Croatian: U
English: ANTITPLATELET AGENTS Ticagrelor
Croatian: ANTITROMBOTICI tikagrelor
English: Tacrolimus
Croatian: Metformin
English: The activity of paritaprevir in genotype 1a was not significantly affected (less than or equal to 3-fold) by single substitutions V36A/M, V55I, Y56H, Q80K or E357K.
Croatian: Pojedinačne supstitucije V36A/M, V55I, Y56H, Q80K i E357K nisu značajno utjecale na aktivnost paritaprevira protiv genotipa 1a (trostruko ili manje).
English: DIURETICS Furosemide
Croatian: ↑ dabigatraneteksilat
English: Mechanism: CYP3A4 inhibition by ritonavir.
Croatian: Mehanizam: CYP3A4 inhibicija ritonavirom.
English: Mechanism: CYP3A4 induction by carbamazepine
Croatian: Mehanizam : Indukcija CYP3A4 karbamazep inom.